Pasireotide

1 study on Pasireotide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on Pasireotide. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

Pasireotide studies and clinical research

2026-04-03 PubMed · in vitro · n preclinical

Targeting SSTR2 Shows Promise for Aggressive SDHB-Deficient Neuroendocrine Tumors

This research identifies SSTR2 as a highly promising therapeutic target for aggressive SDHB-deficient pheochromocytomas and paragangliomas, offering a novel strategy for a disease with limited options. The fact that S…

Research tools

Free, no account — handy when you're working with Pasireotide.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$12 monthly or $33 lifetime

Create free account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

Pasireotide studies and clinical research

Targeting SSTR2 Shows Promise for Aggressive SDHB-Deficient Neuroendocrine Tumors

Research tools